- FY Adjusted EPS Forecast Maintained: Centene continues to project its adjusted earnings per share (EPS) to be above $6.80, with current estimates around $6.85.
- Health Benefits Ratio: The company maintains its outlook for the health benefits ratio to be in the range of 87.3% to 87.9%, with the estimate at the higher end, 87.9%.
- Medicaid Rate Changes: Less than 50% of Medicaid rate changes are anticipated to occur between July 1 and October 1.
- Analyst Recommendations: Current analyst ratings include 11 “buys” and 9 “holds,” with no “sell” recommendations.
A look at Centene Corp Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 1 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on Smartkarma Smart Scores, Centene Corp seems to have a positive long-term outlook. The company scores well in terms of value, resilience, and growth potential. With strong scores in these areas, Centene Corp appears to be positioned for steady growth and stability over the long term. However, the low dividend score may indicate a lack of attractive returns for income-seeking investors. Overall, Centene Corp‘s strategic focus on Medicaid and related programs, along with its specialty health services, positions it well for continued success.
Centene Corporation is a multi-line managed care organization with a presence in multiple states, offering Medicaid and other health-related programs. The company also provides specialized services like behavioral health and nurse triage. With its solid scores in value, growth, and resilience, Centene Corp seems well-equipped to navigate the complexities of the healthcare industry and sustain its growth trajectory in the long term.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
